Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Oct
09
Today In Oncology
John L Cameron Receives Wangensteen Scientific Forum Award
Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
Considerations on Cancer Drug Development
Inflammatory Activity and Cancer-Related Fatigue in Early Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo